Healthcare Industry News: breast implant
News Release - February 1, 2007
UltraShape Appoints Kristine Foss as Vice President Regulatory and Clinical
YOQNEAM, Israel, February 1 (HSMN NewsFeed) -- UltraShape Ltd., industry leader in the body contouring market and the first to market a clinically proven, non-invasive body contouring treatment based on focused ultrasound, announced today the appointment of Kristine Foss as Vice President Regulatory and Clinical. Ms. Foss will lead the company's global regulatory and clinical activities, with a special focus on the company's regulatory strategy in the United States, in addition to maintaining company adherence to all regulatory requirements, and management of the company's global clinical programs.Ms. Foss previously served as Vice President Clinical and Regulatory Affairs at Mentor Corporation, where she successfully secured PMA approval for the company's silicone gel-filled breast implants, one of the most important regulatory milestones in Mentor's history in the aesthetics industry. Previous to that, Ms. Foss served at several leading medical device and pharmaceutical companies in the same position, successfully attaining regulatory approvals and promoting the companies' clinical programs.
"Kris Foss is a welcome addition to the UltraShape management team. Her vast expertise and in-depth knowledge of clinical and regulatory affairs further strengthens our aggressive regulatory strategy," stated Rodger Stewart, UltraShape President and CEO. "Her successful accomplishments with the FDA in the past provide UltraShape with a significant advantage as we work towards our FDA clearance."
"I am looking forward to the opportunity to advance UltraShape's regulatory and clinical process", Ms Foss said. "I am confident we will soon see the results of our successfully implemented regulatory strategy.
About UltraShape
UltraShape, based in Israel, develops and markets the only clinically proven, non-invasive, focused ultrasound solution for body contouring. Thousands of satisfied patients around the world have already enjoyed measurable results.
The Company was founded in 2000 by Dr. Ami Glicksman, a practicing plastic surgeon and Dr. Yoram Eshel, a physicist. The company's first product, Contour I received the CE Mark in June, 2005. The company's revolutionary body contouring solution is based on its patented core technology based on a transducer that delivers controlled focused ultrasound, designed to target and disrupt adipose tissue, leaving surrounding structures within the targeted area such as skin, blood vessels, nerves and connective tissue intact.
The Company has worldwide offices in United States, Israel, France, United Kingdom, and Italy and is currently being marketed in over 40 countries. For more information, please visit www.ultrashape.com
Source: UltraShape
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
